Kymera Therapeutics, Inc. Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Kymera Therapeutics, Inc. (KYMR) holds an ST Score of 51.9 out of 100 (C+), with its strongest factor being Profitability (A-) and its weakest Growth (F). Analysts rate KYMR Buy across 27 ratings with a $136.75 average price target (+0.2% vs the current $117.75).
- Strongest
- ProfitabilityA-
- Weakest
- GrowthF
All factor grades
- ProfitabilityA-
- MomentumB+
- ValuationB-
- Financial StrengthB-
- ForecastB-
- GrowthF
- Piotroski4/9
Contact
KYMR stock: frequently asked questions
What is KYMR's ST Score?
Kymera Therapeutics, Inc. (KYMR) has an ST Score of 51.9 out of 100, an overall grade of C+. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is KYMR a buy, sell, or hold?
Wall Street's consensus rating on KYMR is Buy based on 27 analyst ratings. Our own ST Score grades it C+ (51.9/100). This is data, not investment advice — always do your own research.
What is KYMR's valuation grade?
Kymera Therapeutics, Inc. (KYMR) earns a valuation grade of B-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is KYMR's growth grade?
Kymera Therapeutics, Inc. (KYMR) earns a growth grade of F, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is KYMR's profitability grade?
Kymera Therapeutics, Inc. (KYMR) earns a profitability grade of A-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is KYMR's financial strength grade?
Kymera Therapeutics, Inc. (KYMR) earns a financial strength grade of B-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for KYMR?
The average analyst price target for Kymera Therapeutics, Inc. (KYMR) is $136.75 from 27 analysts, which is +0.2% versus the recent price of $117.75.
What is KYMR's Piotroski score?
Kymera Therapeutics, Inc. (KYMR) has a Piotroski F-Score of 4 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.